Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02330549 · ClinicalTrials.gov registry record · Phase 2
ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or Type 2 Diabetes Mellitus (T2DM) and Suspected NAFLD
A Phase 2 study, sponsored by Tobira Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT02330549 is a Phase 2 study that has completed, run by Tobira Therapeutics. The registered enrollment target is 45 participants.
The verdict
NCT02330549, a Phase 2 study, has completed, sponsored by Tobira Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
A Phase 2a, randomized, double-blind, placebo-controlled, multi-center study of cenicriviroc (CVC) to be conducted in approximately 50 adult obese subjects \[body mass index (BMI) ≥ 30 kg/m\^2\] with prediabetes or type 2 diabetes mellitus and suspected NALFD.
Interventions
- DRUG Placebo
- DRUG Cenicriviroc 150 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2015-07-17 |
| Est. Completion | 2016-09-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02330549
The ClinicalTrials.gov registry entry for NCT02330549 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tobira Therapeutics, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02330549 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02330549 about?
NCT02330549 is a clinical study titled "ORION: Effects of Cenicriviroc on Insulin Sensitivity in Subjects With Prediabetes or Type 2 Diabetes Mellitus (T2DM) and Suspected NAFLD". A Phase 2a, randomized, double-blind, placebo-controlled, multi-center study of cenicriviroc (CVC) to be conducted in approximately 50 adult obese subjects \[body mass index (BMI) ≥ 30 kg/m\^2\] with prediabetes or type 2 diabetes mellitus and suspected NALFD.
What is the current status of trial NCT02330549?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2015-07-17. Estimated completion is 2016-09-08.
What interventions are being tested in trial NCT02330549?
The interventions under investigation include: Placebo (DRUG), Cenicriviroc 150 mg (DRUG).
Who is sponsoring clinical trial NCT02330549?
This trial is sponsored by Tobira Therapeutics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.